Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

GHK-Cu Regulatory Status: US, EU, Canada, and UK Rules for Copper Tripeptide

By
Published Updated Last reviewed
13 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • FDA approval / No FDA-approved drug is known to contain GHK-Cu [2]
  • US topical products / Sold as cosmetics; no FDA premarket approval [1]
  • US injectables / Not a cosmetic, not approved; immunogenicity concern [1][3]
  • Non-injectable compounding status / Category 1, under evaluation for the compounding bulks list [2][4]
  • Injectable compounding status / In the 'nominated but withdrawn' table; not in category 1 [3][2]
  • Next FDA step / Advisory committee review planned before the end of February 2027 [2]
  • EU, Canada, UK / Not covered; no regulator source found

Does FDA approve any GHK-Cu product?

No FDA-approved drug is known to contain GHK-Cu, and FDA treats it as a nominated bulk drug substance rather than an approved medicine [2]. Copper histidinate (Zycubo) was approved on January 12, 2026 for Menkes disease in children, but that is a different compound [5].

Cosmetic or drug? US law looks at intended use

FDA decides by intended use. Cosmetics and cosmetic ingredients other than color additives do not need FDA approval before they are sold, so copper peptide serums and creams sold as cosmetics need no approval [1]. Claims to treat disease, or to change the body's structure or function, make a product a drug instead [1]. An injectable GHK-Cu product is not a cosmetic and is not FDA-approved [1][2]. HealthRX.com offers a copper peptide cream.

Compounding: the answer depends on the route

Non-injectable GHK-Cu is on FDA's list for state-licensed pharmacies and physicians as 'GHK-Cu (except for injectable routes of administration)' in category 1, the group under evaluation for the compounding bulks list, and FDA says it generally does not intend to act against compounders for category 1 substances when the conditions in its guidance are met [2][4]. The entry has changed: it was removed from category 1 on April 22, 2026 when nominations were withdrawn, a nominator clarified on May 5, 2026 that only the injectable route had been withdrawn, and FDA added non-injectable GHK-Cu back, with the list updated May 14, 2026 [2][4].

Injectable GHK-Cu appears in the 'nominated but withdrawn' table of FDA's page on bulk substances that may present significant safety risks, content dated April 22, 2026 [3]. FDA's stated concern: 'Compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities. There are limited data in humans to inform safety-related considerations' [3]. It is not in category 1 and not in any category on FDA's current list [2].

FDA says it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 on whether GHK-Cu belongs on the pharmacy bulks list, and no vote has taken place [2]. GHK-Cu is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy (BPC-157, epitalon, KPV, MOTS-c, Semax, TB-500) [6], and it is not on FDA's list for outsourcing facilities, updated March 21, 2025 [7]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they are marketed [8].

EU, Canada and the UK

We found no source setting out how the EU, Canada or the UK classify GHK-Cu, so this page gives no rules for them. The cosmetic-versus-drug test above is FDA's, under US law [1], and it does not establish what regulators in Brussels, Ottawa or London require for a copper peptide product.

Frequently asked questions

Is GHK-Cu FDA-approved?
No. No FDA-approved drug is known to contain GHK-Cu [2]. Topical copper peptide cosmetics do not need FDA approval before sale, and an injectable GHK-Cu product is not FDA-approved [1].
Are copper peptide serums FDA-approved or FDA-cleared?
No. Cosmetics do not need FDA approval before sale, and a topical product that claimed to treat disease would legally be a drug [1].
Is GHK-Cu banned by the FDA?
No. Non-injectable GHK-Cu is in category 1 of FDA's interim policy, the group under evaluation for the compounding bulks list [2][4]. Injectable GHK-Cu is in the nominated but withdrawn table, with an immunogenicity concern noted [3].
Does the October 2026 HHS peptide policy cover GHK-Cu?
No. That draft policy names six other peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 [6].
Is GHK-Cu prohibited in sport?
It is not named on WADA's 2026 Prohibited List or the 2027 List [12][13]. WADA's S0 class covers substances with no approval from any governmental health authority, and the 2027 notes say peptides not specifically named may still be prohibited [13].

References

  1. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) | FDA
  2. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  3. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA
  4. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA. Bulk Drug Substances Used in Compounding of the FD&C Act | FDA
  5. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  6. Official web page. Official web page
  7. U.S. Food and Drug Administration. U.S. Food and Drug Administration
  8. Official web page. Official web page
  9. Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006;8(4):252-9. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin
  10. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992;16(2):251-7. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers
  11. Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials. Arch Intern Med Res. 2026;9(3):269-293. A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials
  12. World Anti-Doping Agency. World Anti-Doping Agency
  13. World Anti-Doping Agency. World Anti-Doping Agency
Evidence overview for GHK-Cu Regulatory Status: US, EU, Canada, and UK Rules for Copper Tripeptide